Survival analysis plays a key role in many cost-effectiveness analyses, particularly those involving products in oncology.
During this webinar, presenters will provide an introduction to survival analysis, demonstrate why extrapolation is important, and offer an overview of current methods and guidelines. In addition, the webinar will explore the limitations of the standard approaches and suggest more advanced methods to address these limitations. These include multi-state, landmark, and cure modelling, as well as disease-based approaches.

Presented by: Elisabeth Fenwick, Senior Director, Craig Bennison, Associate Director and Sven Klijn, Senior Research Consultant at Pharmerit.

2018-10-29T13:23:44+00:00 October 29th, 2018|